Skip to main content
Erschienen in: Journal of Gastroenterology 7/2019

12.02.2019 | Original Article—Liver, Pancreas, and Biliary Tract

Comprehensive analysis of genetic aberrations linked to tumorigenesis in regenerative nodules of liver cirrhosis

verfasst von: Soo Ki Kim, Haruhiko Takeda, Atsushi Takai, Tomonori Matsumoto, Nobuyuki Kakiuchi, Akira Yokoyama, Kenichi Yoshida, Toshimi Kaido, Shinji Uemoto, Sachiko Minamiguchi, Hironori Haga, Yuichi Shiraishi, Satoru Miyano, Hiroshi Seno, Seishi Ogawa, Hiroyuki Marusawa

Erschienen in: Journal of Gastroenterology | Ausgabe 7/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Hepatocellular carcinoma (HCC) recurrently develops in cirrhotic liver containing a number of regenerative nodules (RNs). However, the biological tumorigenic potential of RNs is still unclear. To uncover the molecular bases of tumorigenesis in liver cirrhosis, we investigated the genetic aberrations in RNs of cirrhotic tissues using next-generation sequencing.

Methods

We isolated 205 RNs and 7 HCC tissues from the whole explanted livers of 10 randomly selected patients who had undergone living-donor liver transplantation. Whole-exome sequencing and additional targeted deep sequencing on 30 selected HCC-related genes were conducted to reveal the mutational landscape of RNs and HCCs.

Results

Whole-exome sequencing demonstrated that RNs frequently harbored relatively high-abundance genetic alterations, suggesting a clonal structure of each RN in cirrhotic liver. The mutation signature observed in RNs was similar to those determined in HCC, characterized by a predominance of C>T transitions, followed by T>C and C>A mutations. Targeted deep sequencing analyses of RNs identified nonsynonymous low-abundance mutations in various tumor-related genes, including TP53 and ARID1A. In contrast, TERT promoter mutations were not detected in any of the RNs examined. Consistently, TERT expression levels in RNs were comparable to those in normal livers, whereas every HCC tissue demonstrated an elevated level of TERT expression.

Conclusion

Analyses of RNs constructing cirrhotic liver indicated that a variety of genetic aberrations accumulate in the cirrhotic liver before the development of clinically and histologically overt HCC. These aberrations in RNs could provide the basis of tumorigenesis in patients with liver cirrhosis.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRefPubMed Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRefPubMed
3.
Zurück zum Zitat Yoshida H, Shiratori Y, Kudo M, et al. Effect of vitamin K2 on the recurrence of hepatocellular carcinoma. Hepatology. 2011;54:532–40.CrossRefPubMed Yoshida H, Shiratori Y, Kudo M, et al. Effect of vitamin K2 on the recurrence of hepatocellular carcinoma. Hepatology. 2011;54:532–40.CrossRefPubMed
4.
Zurück zum Zitat Takeda H, Takai A, Inuzuka T, et al. Genetic basis of hepatitis virus-associated hepatocellular carcinoma: linkage between infection, inflammation, and tumorigenesis. J Gastroenterol. 2017;52:26–38.CrossRefPubMed Takeda H, Takai A, Inuzuka T, et al. Genetic basis of hepatitis virus-associated hepatocellular carcinoma: linkage between infection, inflammation, and tumorigenesis. J Gastroenterol. 2017;52:26–38.CrossRefPubMed
5.
Zurück zum Zitat The International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology. 2009;49:658–64.CrossRef The International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology. 2009;49:658–64.CrossRef
6.
Zurück zum Zitat Shin S, Wangensteen KJ, Teta-Bissett M, et al. Genetic lineage tracing analysis of the cell of origin of hepatotoxin-induced liver tumors in mice. Hepatology. 2016;64:1163–77.CrossRefPubMed Shin S, Wangensteen KJ, Teta-Bissett M, et al. Genetic lineage tracing analysis of the cell of origin of hepatotoxin-induced liver tumors in mice. Hepatology. 2016;64:1163–77.CrossRefPubMed
7.
Zurück zum Zitat Aihara T, Noguchi S, Sasaki Y, et al. Clonal analysis of regenerative nodules in hepatitis C virus-induced liver cirrhosis. Gastroenterology. 1994;107:1805–11.CrossRefPubMed Aihara T, Noguchi S, Sasaki Y, et al. Clonal analysis of regenerative nodules in hepatitis C virus-induced liver cirrhosis. Gastroenterology. 1994;107:1805–11.CrossRefPubMed
8.
Zurück zum Zitat Lin WR, Lim SN, McDonald SA, et al. The histogenesis of regenerative nodules in human liver cirrhosis. Hepatology. 2010;51:1017–26.CrossRefPubMed Lin WR, Lim SN, McDonald SA, et al. The histogenesis of regenerative nodules in human liver cirrhosis. Hepatology. 2010;51:1017–26.CrossRefPubMed
9.
Zurück zum Zitat Ochiai T, Urata Y, Yamano T, et al. Clonal expansion in evolution of chronic hepatitis to hepatocellular carcinoma as seen at an X-chromosome locus. Hepatology. 2000;31:615–21.CrossRefPubMed Ochiai T, Urata Y, Yamano T, et al. Clonal expansion in evolution of chronic hepatitis to hepatocellular carcinoma as seen at an X-chromosome locus. Hepatology. 2000;31:615–21.CrossRefPubMed
10.
Zurück zum Zitat Yasui H, Hino O, Ohtake K, et al. Clonal growth of hepatitis B virus-integrated hepatocytes in cirrhotic liver nodules. Cancer Res. 1992;52:6810–4.PubMed Yasui H, Hino O, Ohtake K, et al. Clonal growth of hepatitis B virus-integrated hepatocytes in cirrhotic liver nodules. Cancer Res. 1992;52:6810–4.PubMed
11.
Zurück zum Zitat Totoki Y, Tatsuno K, Covington KR, et al. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat Genet. 2014;46:1267–73.CrossRefPubMed Totoki Y, Tatsuno K, Covington KR, et al. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat Genet. 2014;46:1267–73.CrossRefPubMed
13.
Zurück zum Zitat Schulze K, Imbeaud S, Letouze E, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet. 2015;47:505–11.CrossRefPubMedPubMedCentral Schulze K, Imbeaud S, Letouze E, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet. 2015;47:505–11.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Goodwin S, McPherson JD, McCombie WR. Coming of age: ten years of next-generation sequencing technologies. Nat Rev Genet. 2016;17:333–51.CrossRefPubMed Goodwin S, McPherson JD, McCombie WR. Coming of age: ten years of next-generation sequencing technologies. Nat Rev Genet. 2016;17:333–51.CrossRefPubMed
15.
Zurück zum Zitat Shimizu T, Marusawa H, Matsumoto Y, et al. Accumulation of somatic mutations in TP53 in gastric epithelium with Helicobacter pylori infection. Gastroenterology. 2014;147:407–17.CrossRefPubMed Shimizu T, Marusawa H, Matsumoto Y, et al. Accumulation of somatic mutations in TP53 in gastric epithelium with Helicobacter pylori infection. Gastroenterology. 2014;147:407–17.CrossRefPubMed
16.
Zurück zum Zitat Ross-Innes CS, Becq J, Warren A, et al. Whole-genome sequencing provides new insights into the clonal architecture of Barrett's esophagus and esophageal adenocarcinoma. Nat Genet. 2015;47:1038–46.CrossRefPubMedPubMedCentral Ross-Innes CS, Becq J, Warren A, et al. Whole-genome sequencing provides new insights into the clonal architecture of Barrett's esophagus and esophageal adenocarcinoma. Nat Genet. 2015;47:1038–46.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Ikeda A, Shimizu T, Matsumoto Y, et al. Leptin receptor somatic mutations are frequent in HCV-infected cirrhotic liver and associated with hepatocellular carcinoma. Gastroenterology. 2014;146:222–32.CrossRefPubMed Ikeda A, Shimizu T, Matsumoto Y, et al. Leptin receptor somatic mutations are frequent in HCV-infected cirrhotic liver and associated with hepatocellular carcinoma. Gastroenterology. 2014;146:222–32.CrossRefPubMed
18.
Zurück zum Zitat Nault JC, Calderaro J, Di Tommaso L, et al. Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology. 2014;60:1983–92.CrossRefPubMed Nault JC, Calderaro J, Di Tommaso L, et al. Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology. 2014;60:1983–92.CrossRefPubMed
19.
Zurück zum Zitat Matsumoto T, Takai A, Eso Y, et al. Proliferating EpCAM-positive ductal cells in the inflamed liver give rise to hepatocellular carcinoma. Cancer Res. 2017;77:6131–43.CrossRefPubMed Matsumoto T, Takai A, Eso Y, et al. Proliferating EpCAM-positive ductal cells in the inflamed liver give rise to hepatocellular carcinoma. Cancer Res. 2017;77:6131–43.CrossRefPubMed
20.
Zurück zum Zitat Ki Kim S, Ueda Y, Hatano E, et al. TERT promoter mutations and chromosome 8p loss are characteristic of nonalcoholic fatty liver disease-related hepatocellular carcinoma. Int J Cancer. 2016;139:2512–8.CrossRefPubMed Ki Kim S, Ueda Y, Hatano E, et al. TERT promoter mutations and chromosome 8p loss are characteristic of nonalcoholic fatty liver disease-related hepatocellular carcinoma. Int J Cancer. 2016;139:2512–8.CrossRefPubMed
21.
Zurück zum Zitat Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478:64–9.CrossRefPubMed Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478:64–9.CrossRefPubMed
22.
23.
Zurück zum Zitat Yoshida K, Toki T, Okuno Y, et al. The landscape of somatic mutations in down syndrome-related myeloid disorders. Nat Genet. 2013;45:1293–9.CrossRefPubMed Yoshida K, Toki T, Okuno Y, et al. The landscape of somatic mutations in down syndrome-related myeloid disorders. Nat Genet. 2013;45:1293–9.CrossRefPubMed
24.
Zurück zum Zitat Mizuguchi A, Takai A, Shimizu T, et al. Genetic features of multicentric/multifocal intramucosal gastric carcinoma. Int J Cancer. 2018;143:1923–34.CrossRefPubMed Mizuguchi A, Takai A, Shimizu T, et al. Genetic features of multicentric/multifocal intramucosal gastric carcinoma. Int J Cancer. 2018;143:1923–34.CrossRefPubMed
27.
Zurück zum Zitat Mu X, Espanol-Suner R, Mederacke I, et al. Hepatocellular carcinoma originates from hepatocytes and not from the progenitor/biliary compartment. J Clin Invest. 2015;125:3891–903.CrossRefPubMedPubMedCentral Mu X, Espanol-Suner R, Mederacke I, et al. Hepatocellular carcinoma originates from hepatocytes and not from the progenitor/biliary compartment. J Clin Invest. 2015;125:3891–903.CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Fujimoto A, Furuta M, Totoki Y, et al. Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer. Nat Genet. 2016;48:500–9.CrossRefPubMed Fujimoto A, Furuta M, Totoki Y, et al. Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer. Nat Genet. 2016;48:500–9.CrossRefPubMed
29.
Zurück zum Zitat Fujimoto A, Furuta M, Shiraishi Y, et al. Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity. Nat Commun. 2015;6:6120.CrossRefPubMed Fujimoto A, Furuta M, Shiraishi Y, et al. Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity. Nat Commun. 2015;6:6120.CrossRefPubMed
30.
Zurück zum Zitat Nault JC, Mallet M, Pilati C, et al. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun. 2013;4:2218.CrossRefPubMed Nault JC, Mallet M, Pilati C, et al. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun. 2013;4:2218.CrossRefPubMed
31.
Zurück zum Zitat Shibata T, Aburatani H. Exploration of liver cancer genomes. Nat Rev Gastroenterol Hepatol. 2014;11:340–9.CrossRefPubMed Shibata T, Aburatani H. Exploration of liver cancer genomes. Nat Rev Gastroenterol Hepatol. 2014;11:340–9.CrossRefPubMed
32.
Zurück zum Zitat Totoki Y, Tatsuno K, Yamamoto S, et al. High-resolution characterization of a hepatocellular carcinoma genome. Nat Genet. 2011;43:464–9.CrossRefPubMed Totoki Y, Tatsuno K, Yamamoto S, et al. High-resolution characterization of a hepatocellular carcinoma genome. Nat Genet. 2011;43:464–9.CrossRefPubMed
33.
Zurück zum Zitat Ally A, Balasundaram M, Carlsen R, Chuah E, Clarke A, Dhalla N, Holt RA, Jones SJ, Lee D, Ma Y, Marra MA. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell. 2017;169:1327–41.CrossRef Ally A, Balasundaram M, Carlsen R, Chuah E, Clarke A, Dhalla N, Holt RA, Jones SJ, Lee D, Ma Y, Marra MA. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell. 2017;169:1327–41.CrossRef
34.
Zurück zum Zitat Eso Y, Marusawa H. Novel approaches for molecular targeted therapy against hepatocellular carcinoma. Hepatol Res. 2018;48:597–607.CrossRefPubMed Eso Y, Marusawa H. Novel approaches for molecular targeted therapy against hepatocellular carcinoma. Hepatol Res. 2018;48:597–607.CrossRefPubMed
35.
Metadaten
Titel
Comprehensive analysis of genetic aberrations linked to tumorigenesis in regenerative nodules of liver cirrhosis
verfasst von
Soo Ki Kim
Haruhiko Takeda
Atsushi Takai
Tomonori Matsumoto
Nobuyuki Kakiuchi
Akira Yokoyama
Kenichi Yoshida
Toshimi Kaido
Shinji Uemoto
Sachiko Minamiguchi
Hironori Haga
Yuichi Shiraishi
Satoru Miyano
Hiroshi Seno
Seishi Ogawa
Hiroyuki Marusawa
Publikationsdatum
12.02.2019
Verlag
Springer Japan
Erschienen in
Journal of Gastroenterology / Ausgabe 7/2019
Print ISSN: 0944-1174
Elektronische ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-019-01555-z

Weitere Artikel der Ausgabe 7/2019

Journal of Gastroenterology 7/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.